Deze pagina is automatisch vertaald en de nauwkeurigheid van de vertaling kan niet worden gegarandeerd. Raadpleeg de Engelse versie voor een brontekst.

EEN-UUR POSITIEVE DRUK BEADEMING NA EEN T-STUK SPONTANE ADEMHALINGSPROEF: EEN GERANDOMISEERDE KLINISCHE STUDIE (GS-Wean Tpiece)

18 september 2026 bijgewerkt door: Hospital do Coracao

EENUUR POSITIEVE DRUK BEADEMING NA EEN T-STUK SPONTANE ADEMHALINGSPROEF: EEN GERANDOMISEERDE KLINISCHE STUDIE

This is a randomized, open, multicenter, pragmatic, adaptive clinical trial with intention-to-treat analysis. The study will compare two weaning strategies from mechanical ventilation in critically ill patients admitted to intensive care units, with more than 72 hours of mechanical ventilation and with a successful spontaneous breathing trial on T-piece. Immediately after a successful spontaneous breathing trial, eligible patients will be randomized into 2 groups that will be treated according to one of the following interventions:

  1. One-hour positive pressure ventilation: as soon as the success of the spontaneous breathing trial is confirmed, the patient is submitted to mechanical ventilation for 1 hour using the previous ventilatory parameters and, afterwards, extubated.
  2. Immediate extubation: the patient is extubated immediately after the success of the spontaneous breathing trial.

Studie Overzicht

Gedetailleerde beschrijving

Adaptive design for sample size. The study will include up to a maximum of 4.000 patients. First interim analysis will be performed after complete data is available for the first 500 eligible patients. The Bayesian logistic regression model will be adjusted to provide posterior probabilities that will be compared with threshold values to evaluate stopping decisions. Extensive simulations were conducted to develop and understand adaptive design performance, interim analysis timing, and decision criteria. The trial may be stopped early for efficacy or futility. Secondary outcomes will be analyzed with a gatekeeping procedure to preserve overall type I error at 0.05. Thus, the assessment of statistical significance of secondary outcomes will be performed only if the preceding outcome in the hierarchy met the threshold for statistical significance. No adjustment for multiple comparisons will be applied for analyses of tertiary outcomes and subgroups. Thus, these results should be interpreted as exploratory. Secondary outcomes tested in hierarchical order will be: (1) Mechanical ventilation free days within 28 days; (2) Hospital free days within 28 days; (3) Mortality within 28 days.

Studietype

Ingrijpend

Inschrijving (Geschat)

4000

Fase

  • Niet toepasbaar

Contacten en locaties

In dit gedeelte vindt u de contactgegevens van degenen die het onderzoek uitvoeren en informatie over waar dit onderzoek wordt uitgevoerd.

Studiecontact

Deelname Criteria

Onderzoekers zoeken naar mensen die aan een bepaalde beschrijving voldoen, de zogenaamde geschiktheidscriteria. Enkele voorbeelden van deze criteria zijn iemands algemene gezondheidstoestand of eerdere behandelingen.

Geschiktheidscriteria

Leeftijden die in aanmerking komen voor studie

18 jaar en ouder (Volwassen, Oudere volwassene)

Accepteert gezonde vrijwilligers

Nee

Geslachten die in aanmerking komen voor studie

Allemaal

Beschrijving

Inclusion Criteria:

  • Patients aged > 18 years.
  • Admitted to the intensive care unit (surgical or medical).
  • With endotracheal intubation.
  • Mechanical ventilation for more than 72 hours.
  • Who underwent successful spontaneous breathing trial (according to the study protocol) and is considered able to be extubated.

Exclusion Criteria:

  • Patients unable to obey commands.
  • With non-planned extubation.
  • Neuromuscular disease and cervical spinal cord injury.
  • Tracheostomy.
  • Contraindication for cardiopulmonary resuscitation or reintubation.
  • Terminal extubation.
  • Lack of informed consent.
  • Previously included in the trial.

Studie plan

Dit gedeelte bevat details van het studieplan, inclusief hoe de studie is opgezet en wat de studie meet.

Hoe is de studie opgezet?

Ontwerpdetails

  • Primair doel: Preventie
  • Toewijzing: Gerandomiseerd
  • Interventioneel model: Parallelle opdracht
  • Masker: Geen (open label)

Wapens en interventies

Deelnemersgroep / Arm
Interventie / Behandeling
Experimenteel: Eén uur positieve drukventilatie

As soon as the success of the spontaneous breathing trial is confirmed, the patient is submitted to mechanical ventilation for 1 hour using the previous ventilatory parameters and, afterwards, extubated.

Actieve vergelijker: Onmiddellijke extubatie

The patient is extubated immediately after the success of the spontaneous breathing trial.

Wat meet het onderzoek?

Primaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Number of Participants With Extubation Failure Within 7 Days
Tijdsspanne: 7 days (from randomization through Day 7 after randomization)

Extubation failure is defined as a composite endpoint of reintubation or death within 7 days after randomization.

7 days (from randomization through Day 7 after randomization)

Secundaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Ventilator-Free Days Through Day 28
Tijdsspanne: 28 days (from randomization through Day 28 after randomization)

Ventilator-free days are defined as the number of days alive and free from invasive mechanical ventilation from randomization through Day 28 after randomization. If a patient dies before day 28, the ventilator-free days will be counted as zero. If a patient is reintubated and returns to mechanical ventilation and later is extubated again and remains in unassisted breathing until day 28, the ventilator-free days will be counted from the end of the last period of assisted breathing until day 28. An invasive mechanical ventilation period of less than 24 hours for surgical purposes will count as 1 ventilator-free day. Patients discharged from the hospital in unassisted breathing before 28 days will be considered alive and free from mechanical ventilation for the remaining days up to 28 days. Patients transferred to another hospital or healthcare unit will be followed up until day 28 to assess this outcome.

28 days (from randomization through Day 28 after randomization)
Hospital-Free Days Through Day 28
Tijdsspanne: 28 days (from randomization through Day 28 after randomization)

Hospital-free days are defined as the number of days alive and out of the hospital from randomization through Day 28 after randomization. If a patient dies before day 28, the hospital-free days will be counted as zero. Patients discharged from the hospital in unassisted breathing before 28 days will be considered alive and free from hospital for the remaining days up to 28 days. Patients transferred to another hospital or healthcare unit will be followed through day 28 to ascertain this outcome.

28 days (from randomization through Day 28 after randomization)
Number of Participants Who Died Within 28 Days
Tijdsspanne: 28 days (from randomization through Day 28 after randomization)

All-cause mortality from randomization through day 28

28 days (from randomization through Day 28 after randomization)

Andere uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Ventilatory Support-Free Days Through Day 28
Tijdsspanne: 28 days (from randomization through Day 28 after randomization)

Ventilatory support-free days are defined as the number of days alive and free from any ventilatory support (invasive or noninvasive) from randomization through day 28. Any use of invasive mechanical ventilation for any duration during a calendar day will count as 1 day with ventilatory support (i.e., not free). Use of noninvasive ventilatory support (noninvasive ventilation or high-flow nasal cannula) for ≥6 hours in any calendar day will count as 1 day with ventilatory support. Participants who die before day 28 will be assigned 0 ventilatory support-free days. If reintubation occurs and the participant later achieves unassisted spontaneous breathing again, ventilatory support-free days will be counted from the end of the last assisted-breathing period through day 28, provided the participant remains alive and free from ventilatory support.

28 days (from randomization through Day 28 after randomization)
Number of Participants With Extubation Failure Within 2 Days
Tijdsspanne: 2 days (from randomization through Day 2 after randomization)

Extubation failure is defined as a composite endpoint of reintubation or death within 2 days after randomization

2 days (from randomization through Day 2 after randomization)
Number of Participants With Death or Reintubation Within 28 Days
Tijdsspanne: 28 days (from randomization through Day 28 after randomization)

Composite endpoint of reintubation or death within 28 days after randomization

28 days (from randomization through Day 28 after randomization)
Intensive Care Unit-Free Days Through Day 28
Tijdsspanne: 28 days (from randomization through Day 28 after randomization)

ICU-free days are defined as the number of days alive and out of the intensive care unit from randomization through day 28. If a patient dies before day 28, the ICU-free days will be counted as zero. Patients discharged from the hospital in unassisted breathing before 28 days will be considered as alive and free from ICU for the remaining days up to 28 days. Patients transferred to another hospital or healthcare unit will be followed up until day 28 to assess this outcome.

28 days (from randomization through Day 28 after randomization)
Number of Participants Who Died in the Intensive Care Unit
Tijdsspanne: From randomization to ICU discharge, up to 90 days

All-cause mortality occurring from randomization until ICU discharge (death before ICU discharge).

From randomization to ICU discharge, up to 90 days
Number of Participants Who Died in the Hospital
Tijdsspanne: From randomization to hospital discharge, up to 90 days

All-cause mortality occurring from randomization until hospital discharge (death before hospital discharge)

From randomization to hospital discharge, up to 90 days

Medewerkers en onderzoekers

Hier vindt u mensen en organisaties die betrokken zijn bij dit onderzoek.

Studie record data

Deze datums volgen de voortgang van het onderzoeksdossier en de samenvatting van de ingediende resultaten bij ClinicalTrials.gov. Studieverslagen en gerapporteerde resultaten worden beoordeeld door de National Library of Medicine (NLM) om er zeker van te zijn dat ze voldoen aan specifieke kwaliteitscontrolenormen voordat ze op de openbare website worden geplaatst.

Bestudeer belangrijke data

Studie start (Geschat)

1 januari 2027

Primaire voltooiing (Geschat)

1 december 2029

Studie voltooiing (Geschat)

1 februari 2030

Studieregistratiedata

Eerst ingediend

23 december 2025

Eerst ingediend dat voldeed aan de QC-criteria

23 december 2025

Eerst geplaatst (Werkelijk)

7 januari 2026

Updates van studierecords

Laatste update geplaatst (Werkelijk)

22 september 2026

Laatste update ingediend die voldeed aan QC-criteria

18 september 2026

Laatst geverifieerd

1 september 2026

Meer informatie

Termen gerelateerd aan deze studie

Informatie over medicijnen en apparaten, studiedocumenten

Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel

Nee

Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct

Nee

Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .

Abonneren